PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Genomic analyses point to the potential of personalised care for liver cancer patients

Use of exome sequencing helps determine which hepatocellular carcinoma patients could benefit from targeted anticancer treatments

2015-04-23
(Press-News.org) April 23, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.

Using exome sequencing - a technique for sequencing all the protein-coding genes in a genome - the study identified relationships between environmental exposures, such as tobacco smoke and alcohol use, and mutational patterns in HCC. It also determined the landscape of driver genes and pathways altered in different clinical stages and aetiological backgrounds. Out of eight mutational signatures identified in the study, two new mutational signatures for HCC were found.

Professor Jessica Zucman-Rossi, director of the INSERM/university Paris Descartes "Functional Genomics of Solid Tumors" laboratory explained: "Mutational signatures help with understanding the biological history of a cancer and can enable differentiation between ongoing mutational processes and historical ones. This helps identify potential new targets for anticancer therapies."

In the study, most patients had at least one damaging alteration which could potentially be treated with either an FDA-approved drug (28% of patients) or an investigational drug (86% of patients) which has been studied in Phase I to Phase III clinical trials.

"Hepatocarcinogenesis is a multi-step process in which pre-cancerous lesions can ultimately transform into liver cancer. Genomic analyses, such as exome sequencing, allow us to better understand the mutational processes involved in the development of cancers. This detailed knowledge then helps us to unravel the mutagenic processes and to optimise personalised patient care," said Professor Markus Peck, Secretary General, European Association for the Study of the Liver.

The study authors hope that the use of exome sequencing will lead to the identification of potential new targets for anticancer therapy and create optimised personalised patient care.

INFORMATION:

About The International Liver Congress™ This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.

About EASL Since EASL's foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

Contact For more information, please contact the ILC Press Office at: ilc.press@easloffice.eu or
+44 (0)20 3580 5444



ELSE PRESS RELEASES FROM THIS DATE:

Combination therapy offers new hope for difficult-to-treat patients with chronic hepatitis C

2015-04-23
April 23, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation. SOLAR 2 data are presented for 328 HCV genotype-1 or -4 treatment-naive or treatment-experienced ...

Pooled analysis confirms vitamin E as a treatment for non-alcoholic steatohepatitis

2015-04-23
April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis. A pooled analysis of data from two randomised trials comparing vitamin E versus placebo, and the placebo group from another ...

New survey shows that half of people with hepatitis suffer from discrimination

2015-04-23
April 23, 2015, Vienna, Austria: As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver CongressTM 2015 has shown the devastating impact the infection has on their daily lives. Research conducted with the Ministry of Health in Brazil questioned 1,217 people infected with hepatitis B or C in Europe and America using an online survey tool. The aim of the research ...

Investigational anti-diabetic may offer potential for management of non-alcoholic fatty liver

2015-04-23
April 23, 2015, Vienna, Austria: Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). In clinical studies, remogliflozin etabonate was shown to significantly improve insulin sensitivity and beta cell function, as well as reduce body weight and levels of alanine aminotransferase (ALT). In pre-clinical studies, remogliflozin ...

Preliminary results show Civacir prevents recurrence of hepatitis C in liver transplants

2015-04-23
April 23, 2015, Vienna, Austria: New data from an ongoing Phase III trial revealed today at The International Liver CongressTM 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir®) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT). The data demonstrate that intravenous Civacir given both peri- and post-LT prevents HCV-reinfection in patients who also received antiviral therapy (AVT) before their transplant operation. Civacir is a hepatitis C immune globulin (HCIG) produced from pooled plasma ...

Herbal remedy derived from milk thistle demonstrates efficacy in non-alcoholic steatohepatitis

2015-04-23
April 23, 2015, Vienna, Austria: Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH). An interim analysis of the study, revealed today at The International Liver Congress™ 2015, shows a significantly higher percentage of patients experienced NASH resolution and improvement in fibrosis after 48 weeks of treatment with silymarin compared to placebo. NASH occurs when the liver becomes inflamed ...

Many European countries ill-prepared to prevent and control the spread of viral hepatitis

2015-04-23
April 23, 2015, Vienna, Austria: Many countries in the World Health Organization (WHO) European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress™ 2015. The study highlights that less than one-third (27%) of WHO European Member States have national strategies in place that contain a surveillance component. Furthermore, only 64% have a national surveillance system for chronic hepatitis ...

All-oral, direct-acting antivirals show promise for hep C and HIV co-infected, cirrhotic patients

2015-04-23
April 23, 2015, Vienna, Austria: A new study revealed today at The International Liver CongressTM 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12). The results are particularly encouraging as this patient group is considered difficult-to-treat and has a high mortality rate. The study included 142 patients of different hepatitis C virus (HCV) genotypes who were initiated onto ...

All-oral, DAA options for HCV effective & well tolerated in patients with decompensated cirrhosis

2015-04-23
April 23, 2015, Vienna, Austria: Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response (SVR) at 4 weeks was shown to be: sofosbuvir/ribavirin: 75%; sofosbuvir/simeprevir: 77%; sofosbuvir/simeprevir/ribavirin: 81%. These results demonstrate that all-oral, direct-acting antiviral regimens are better tolerated and achieve higher rates of SVR in HCV ...

Delaying treatment for hepatitis C puts patients' lives at risk

2015-04-23
April 23, 2015, Vienna, Austria: Data revealed today at The International Liver Congress™ 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on treatment efficacy, increasing the risk of morbidity and mortality among patients. The study was conducted using retrospective patient data from the Veterans Administration in the USA to estimate the impact on risk of morbidity and death depending on whether treatment was initiated before or after a patient's FIB4 levels ...

LAST 30 PRESS RELEASES:

Post-LLM era: New horizons for AI with knowledge, collaboration, and co-evolution

“Sloshing” from celestial collisions solves mystery of how galactic clusters stay hot

Children poisoned by the synthetic opioid, fentanyl, has risen in the U.S. – eight years of national data shows

USC researchers observe mice may have a form of first aid

VUMC to develop AI technology for therapeutic antibody discovery

Unlocking the hidden proteome: The role of coding circular RNA in cancer

Advancing lung cancer treatment: Understanding the differences between LUAD and LUSC

Study reveals widening heart disease disparities in the US

The role of ubiquitination in cancer stem cell regulation

New insights into LSD1: a key regulator in disease pathogenesis

Vanderbilt lung transplant establishes new record

Revolutionizing cancer treatment: targeting EZH2 for a new era of precision medicine

Metasurface technology offers a compact way to generate multiphoton entanglement

Effort seeks to increase cancer-gene testing in primary care

Acoustofluidics-based method facilitates intracellular nanoparticle delivery

Sulfur bacteria team up to break down organic substances in the seabed

Stretching spider silk makes it stronger

Earth's orbital rhythms link timing of giant eruptions and climate change

Ammonia build-up kills liver cells but can be prevented using existing drug

New technical guidelines pave the way for widespread adoption of methane-reducing feed additives in dairy and livestock

Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza

New study finds that tooth size in Otaria byronia reflects historical shifts in population abundance

nTIDE March 2025 Jobs Report: Employment rate for people with disabilities holds steady at new plateau, despite February dip

Breakthrough cardiac regeneration research offers hope for the treatment of ischemic heart failure

Fluoride in drinking water is associated with impaired childhood cognition

New composite structure boosts polypropylene’s low-temperature toughness

While most Americans strongly support civics education in schools, partisan divide on DEI policies and free speech on college campuses remains

Revolutionizing surface science: Visualization of local dielectric properties of surfaces

LearningEMS: A new framework for electric vehicle energy management

Nearly half of popular tropical plant group related to birds-of-paradise and bananas are threatened with extinction

[Press-News.org] Genomic analyses point to the potential of personalised care for liver cancer patients
Use of exome sequencing helps determine which hepatocellular carcinoma patients could benefit from targeted anticancer treatments